Universität zu Köln

van Wezel, Esther M., Decarolis, Boris ORCID: 0000-0002-1607-0543, Stutterheim, Janine, Zappeij-Kannegieter, Lily, Berthold, Frank ORCID: 0000-0002-7613-1723, Schumacher-Kuckelkorn, Roswitha, Simon, Thorsten, Fiocco, Marta, van Noesel, Max M., Caron, Huib N., van der Schoot, C. Ellen, Hero, Barbara and Tytgat, Godelieve A. M. (2016). Neuroblastoma messenger RNA is frequently detected in bone marrow at diagnosis of localised neuroblastoma patients. Eur. J. Cancer, 54. S. 149 - 159. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852

Full text not available from this repository.

Abstract

Introduction: The clinical importance of the detection of neuroblastoma messenger RNA (mRNA) in bone marrow (BM) of localised neuroblastoma patients at diagnosis remains unclear. In this prospective multicentre study, BM samples of a large cohort, were studied using real-time quantitative polymerase chain reaction (qPCR). Methods: BM samples at diagnosis from 160 patients with localised neuroblastoma were prospectively collected at Dutch and German centres between 2009 and 2013. qPCR was performed using five neuroblastoma specific markers. The association with other biological factors and the prognostic impact of BM positivity and clinical response was assessed. Results: In 58 out of 160 patients neuroblastoma mRNA was detected in BM. In 47 of the 58 positive samples only one marker was found positive. BM positivity was significantly associated with MYCN amplification (p = 0.02) and deletion of chromosome 1p (p = 0.04). In total 31 patients had an event, of which only five patients had progression to stage IV. BM positivity was not associated with an unfavourable outcome. However, the detection of more than one marker was associated with an unfavourable outcome (systemic or local relapse) (event free survival 48% versus 85%; p = 0.03) in the whole cohort and in the observation group. Conclusions: BM positivity was associated with unfavourable biological factors and might represent more aggressive tumours. Patients with qPCR positive BM should not be upstaged, because of very few systemic events in the cohort. However, for patients with more than one marker positive a more careful follow-up is advisable. These results need to be verified in a very large cohort of localised patients. (C) 2015 Elsevier Ltd. All rights reserved.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code van Wezel, Esther M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Decarolis, Boris UNSPECIFIED orcid.org/0000-0002-1607-0543 UNSPECIFIED Stutterheim, Janine UNSPECIFIED UNSPECIFIED UNSPECIFIED Zappeij-Kannegieter, Lily UNSPECIFIED UNSPECIFIED UNSPECIFIED Berthold, Frank UNSPECIFIED orcid.org/0000-0002-7613-1723 UNSPECIFIED Schumacher-Kuckelkorn, Roswitha UNSPECIFIED UNSPECIFIED UNSPECIFIED Simon, Thorsten UNSPECIFIED UNSPECIFIED UNSPECIFIED Fiocco, Marta UNSPECIFIED UNSPECIFIED UNSPECIFIED van Noesel, Max M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Caron, Huib N. UNSPECIFIED UNSPECIFIED UNSPECIFIED van der Schoot, C. Ellen UNSPECIFIED UNSPECIFIED UNSPECIFIED Hero, Barbara UNSPECIFIED UNSPECIFIED UNSPECIFIED Tytgat, Godelieve A. M. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-285849
DOI:	10.1016/j.ejca.2015.11.007
Journal or Publication Title:	Eur. J. Cancer
Volume:	54
Page Range:	S. 149 - 159
Date:	2016
Publisher:	ELSEVIER SCI LTD
Place of Publication:	OXFORD
ISSN:	1879-0852
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language MINIMAL RESIDUAL DISEASE; METASTATIC NEUROBLASTOMA; PROGNOSTIC VALUE; NEURO-BLASTOMA; TASK-FORCE; STAGE-II; N-MYC; PCR; CELLS; HISTOLOGY Multiple languages Oncology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/28584